Revolution Medicines CEO sells 13,988 shares

RVMD’s CEO and director Mark A. Goldsmith sold 13,988 shares under a Rule 10b5-1 plan to cover tax withholding from vesting restricted stock units.

Rhea-AI Filing Summary

Revolution Medicines, Inc. (RVMD) reported that President and Chief Executive Officer Mark A. Goldsmith, who is also a director, sold 13,988 shares of common stock on September 16, 2026 in open-market transactions. The sales were made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding obligations upon the vesting of restricted stock units.

The transactions occurred at weighted-average prices of $195.01 and $199.30 per share across multiple trades. Goldsmith also has indirect holdings in family trusts, including the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust and revocable trusts for Jonathan and Rebecca Goldsmith.

Insider Trade Summary 10b5-1

Net Seller: 13,988 shares

Net Sell 5 txns

Insider GOLDSMITH MARK A

Role See Remarks

Sold 13,988 shs ($2.79M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	213	$195.0085	$42K
Sale	Common Stock F1, F3	13,775	$199.3032	$2.75M
holding	Common Stock F4	--	--	--
holding	Common Stock F5	--	--	--
holding	Common Stock F6	--	--	--

Holdings After Transaction: Common Stock — 253,342 shares (Direct); Common Stock — 716,908 shares (Indirect, Trust)

Footnotes (6)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.
2. F2. The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. Includes 157,588 restricted stock units.
4. F4. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.
5. F5. Held by Jonathan Goldsmith Revocable Trust.
6. F6. Held by Rebecca Goldsmith Revocable Trust.

Key Figures

Shares sold: 13,988 shares First transaction price: $195.01 per share Second transaction price: $199.30 per share +2 more

5 metrics

Shares sold 13,988 shares Total RVMD common shares sold by Mark A. Goldsmith on September 16, 2026

First transaction price $195.01 per share Weighted-average sale price for 213 shares; individual trades ranged $195.00–$195.03

Second transaction price $199.30 per share Weighted-average sale price for 13,775 shares

Rule 10b5-1 adoption date May 31, 2023 Date the instruction letter governing these sales was adopted

Restricted stock units included 157,588 restricted stock units RSUs included in the CEO’s reported holdings after the transactions

Key Terms

Rule 10b5-1, restricted stock units, Revocable Living Trust

3 terms

Rule 10b5-1 regulatory

"Transaction made pursuant to a Rule 10b5-1 instruction letter adopted"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

restricted stock units financial

"Includes 157,588 restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Revocable Living Trust financial

"Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did RVMD report for CEO Mark A. Goldsmith?

RVMD reported that Mark A. Goldsmith sold 13,988 shares of common stock on September 16, 2026 in open-market transactions, executed under a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy tax withholding on vesting restricted stock units.

At what prices were the RVMD shares sold in this Form 4 filing?

The 13,988 RVMD shares were sold at weighted-average prices of $195.01 and $199.30 per share. One trade was executed in multiple transactions between $195.00 and $195.03, with the reported price reflecting the weighted-average sale price for that range.

Was the RVMD Form 4 sale by the CEO under a Rule 10b5-1 plan?

Yes. The filing and footnotes state the sale was made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the reporting person’s tax withholding obligation upon vesting of restricted stock units.

How many RVMD shares did the CEO sell in each transaction?

Mark A. Goldsmith sold 213 shares of RVMD common stock at a weighted-average price of $195.01 per share and 13,775 shares at a weighted-average price of $199.30 per share, for a total of 13,988 shares sold on September 16, 2026.

What do the footnotes say about the CEO’s remaining RVMD equity?

One footnote states the CEO’s reported holdings include 157,588 restricted stock units. Additional footnotes explain that other RVMD shares are held indirectly in family trusts, including the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust and revocable trusts for Jonathan and Rebecca Goldsmith.

Were the RVMD CEO’s sales related to tax withholding?

Yes. A footnote explains that the transactions were made under a Rule 10b5-1 instruction letter to satisfy the reporting person’s tax withholding obligation arising from the vesting of restricted stock units, rather than as discretionary open-market sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/18/2026 - 06:02 PM Accepted by SEC EDGAR 09/18/2026 - 06:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last) (First) (Middle)

REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2026		S(1)		213	D	$195.0085(2)	267,117	D
Common Stock	09/16/2026		S(1)		13,775	D	$199.3032	253,342(3)	D
Common Stock								594,060	I	Trust(4)
Common Stock								61,424	I	Trust(5)
Common Stock								61,424	I	Trust(6)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

2. The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 157,588 restricted stock units.

4. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

5. Held by Jonathan Goldsmith Revocable Trust.

6. Held by Rebecca Goldsmith Revocable Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in-fact for Mark A. Goldsmith, M.D., Ph.D.	09/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)